eFFECTOR Therapeutics Inc · OTC:EFTR

eFFECTOR Therapeutics — SPAC Merger (May 2021)

50 slides from eFFECTOR Therapeutics's SPAC merger presentation, May 27, 2021

  1. Slide 1: Corporate Overview May 2021

    Corporate Overview May 2021 Next Generation Targeted Therapy for Cancer Exhibit 99.2

  2. Slide 2: Disclaimer

    Disclaimer 1 ABOUT THIS PRESENTATION This presentation is for informational purpose sonly to assist interested parties in making their own evaluation with respect to a proposed business combination (the Business Combination) between Locust Walk Acquisition Corp. (LWAC) and eFFECTOR Therapeutics, Inc

  3. Slide 3: Executive Summary

    EXECUTIVE SUMMARY Pioneering Selective Translation Regulator Inhibitors (STRIs) – a leading company targeting MNK and eIF4F complex MNK drives production of checkpoint proteins including PD-1, PD-L1, LAG-3 and TIM-3 eIF4F is a key node where the RAS and PI3K pathways converge to drive production of

  4. Slide 4: eFFECTOR Meets Demanding Criteria of Locust Walk Acquisition Corp

    eFFECTOR MEETS DEMANDING CRITERIA OF LOCUST WALK ACQUISITION CORP Locust Walk Acquisition Corp (LWAC) is a $175M SPAC focused on biotechnology with a comprehensive investment thesis that has been used to evaluate over 90 potential targets SUPERLATIVE CRITERIA Validating Partnership Novel Lead Asset

  5. Slide 5: eFFECTOR Pipeline: Multiple STRIs in development

    eFFECTOR Pipeline: Multiple STRIs in development Program (Target) Discovery Preclinical Phase 1 Phase 2 Phase 3 Global Rights Anticipated Milestones U.S. addressable population Tomivosertib (MNK 1/2i) Zotatifin (elF4Ai) eIF4Ei NSCLC – 1L Extension in combo with pembro Solid Tumors RTK BC and KRAS NS

  6. Slide 6: Targeting Key Node in Cancer Controlling Cell Growth and Proliferation

    Targeting Key node in cancer controlling Cell Growth and proliferation eIF4F complex is a central node where two highly validated cancer pathways converge to activate production of onco-proteins involved in growth, proliferation and survival of tumor cells MNK activates eIF4F and drives T cell exhau

  7. Slide 7: Platform, chemistry, culture and upcoming value inflection events

    Foundation Platform – mRNA translation biology from UCSF Chemistry – world class SBDD expertise Culture – rigorous science and capital efficiency Next 12-24 months Tomi – definitive PoC for pembro combination Zota – ORR data from expansion cohorts Zota COVID – obtain human antiviral PoC data eIF4E –

  8. Slide 8: Experienced leadership team and scientific advisors

    Steve Worland, Ph.D. Founder, President, CEO and Director Premal Patel, M.D., Ph.D. CMO Alana McNulty CBO Mike Byrnes CFO Experienced leadership team Scientific Advisors Institution Expertise Kevan Shokat, PhD UCSF, eFFECTOR Co-founder Translation & KRAS Davide Ruggero, PhD UCSF, eFFECTOR Co-founder

  9. Slide 9: Tomivosertib (eFT508)

    Tomivosertib (eFT508) Designed to stimulate activation, prevent exhaustion and prolong memory of T cells MNK 1/2 Inhibitor

  10. Slide 10: Tomivosertib – inhibiting MNK 1/2 kinase promotes T cell activity

    T Cells Continuous activation of TCR leads to feedback mechanisms involving MNK that result in T cell exhaustion/dysfunction Delaying or reversing T cell exhaustion is a highly sought-after attribute in new IO products to extend benefit of PD-(L)1 agents Highly selective MNK inhibitor, tomivosertib,

  11. Slide 11: Tomivosertib Triggered Anti-Tumor Activity and Enhanced PD-1 Blockade In Vivo

    TOMIVOSERTIB TRIGGERED ANTI-TUMOR ACTIVITY AND ENHANCED THE ACTIVITY OF PD-1 CHECKPOINT BLOCKADE IN VIVO Tumor biopsies from eFT508 treated animals showed an increased ratio of CD8+ T cells to FOXP3+ T cells (Tregs) and a decreased M2 macrophage population Tomivosertib downregulated multiple checkpo

  12. Slide 12: Tomivosertib Clinical Overview

    Tomivosertib clinical Overview* Tomivosertib was generally well tolerated at RP2D as single agent and in combination with anti-PD-(L)1 agents The most common drug-related side effects have included low grade nausea, vomiting, fatigue and tremors Safety results when combined with anti-PD-(L)1 agents

  13. Slide 13: Tomivosertib Demonstrated Prolonged PFS with Anti-PD-(L)1 Agents

    Tomivosertib demonstrated prolonged pfs when combined with anti-PD-(L)1 agents Phase 2a study combined with anti-PD-(L)1 demonstrated encouraging activity* Tomivosertib was added to patients not responding to ongoing anti-PD-(L)1 therapy with no change or break in anti-PD-(L)1 regimen Confirmed PR o

  14. Slide 14: Phase 2a Results Suggest Potential to Reverse Resistance

    Tomi + Pembro Pembro mono Transferred to individual IND phase 2a results suggest tomivosertib’s potential to reverse resistance to anti-PD-(L)1 therapy Data through study completion in September 2020. Includes all evaluable patients with at least one on treatment scan (n=16). Patients 115-103 and 12

  15. Slide 15: Patient on Tomi/Pembro Combo Experienced Confirmed Complete Response

    Patient on Tomi/Pembro Combo Experienced Confirmed Complete Response after ~2 Years on Combo Tx

  16. Slide 16: Demonstrated PFS in NSCLC Patients

    Demonstrated PFS in NSCLC patients Median of 2 prior therapies for metastatic disease prior to addition of tomivosertib Median PFS = 20 weeks, mOS 19.0 months 9 of 17 patients (53%) remained on study ≥ 24 weeks Comparator data set from OAK study Treatment Beyond Progression cohort* ─ median ~7 weeks

  17. Slide 17: PD-L1 Positive Patients Showed Longer PFS

    PD-L1 positive patients showed longer PFS Data through study completion in September 2020 Patients 115-103 and 120-103 continued treatment past study completion on Single Patient Expanded Access INDs

  18. Slide 18: PD-L1 Positive Patients Showed Longer PFS

    Pd-l1 positive patients showed longer pfs A post-hoc analysis showed that PD-L1 positive patients had three times lower risk of progression than PD-L1 negative patients in Phase 2a study In the OAK treatment beyond progression cohort, PD-L1 status was not correlated with benefit of continued treatme

  19. Slide 19: Plan to Evaluate Novel Treatment Setting – 1L Extension NSCLC

    Plan to evaluate novel treatment setting – 1L Extension Nsclc Based on our 17 NSCLC patient data, we received FDA allowance to proceed with the following 1L extension study Tomivosertib added to pembrolizumab after initial progression In patients suitable to continue on pembrolizumab after PD Contro

  20. Slide 20: Randomized Phase 2b KICKSTART Trial Design

    ~ 120 patients will be enrolled in a randomized Phase 2b trial, with 2 independent cohorts: Front line extension – combo post initial PD on pembrolizumab Front line combo treatment with pembrolizumab Stage IV NSCLC PD-L1 50% No prior chemo Tomivosertib + pembrolizumab Placebo + pembrolizumab Key end

  21. Slide 21: P2A vs P2B KICKSTART Comparison

    P2A (completed) P2B KICKSTART (ongoing) Patient Population Patients were on any approved PD-(L)1 therapy and allowed prior chemo Pembrolizumab only, no prior chemo in the metastatic setting PD-L1 Status Any PD-L1 level eligible, including PD-L1 negative patients who had shorter PFS Only enrolling PD

  22. Slide 22: Potential Market Settings – PD-L1 > 50%

    Pembro Monotherapy ≥ 50% PD-L1 Advanced/Metastatic NSCLC w/ No Actionable Mutations Platinum Doublet ± Pembrolizumab Docetaxel ± Ramucirumab Lenvatinib + Pembrolizumab Sitravatinib + Nivolumab 2L salvage therapy alternatives Novel Setting: Tomi + pembro – 1L Extension (reverse resistance) US address

  23. Slide 23: Zotatifin (eFT226) eIF4A Helicase Inhibitor – Oncology

    Zotatifin (eFT226) eIF4A Helicase Inhibitor Oncology: Designed to downregulate key oncoproteins and cell cycle proteins

  24. Slide 24: Zotatifin Designed to Inhibit Production of Key Proteins

    4A- translationally regulated genes including RTKs, KRAS, ER, Cyclin D1, CDK4/6 Zotatifin DESIGNED TO inhibit production of key proteins driven by upstream oncogenes eIF4A is activated by upstream oncogenic signaling and regulates synthesis of key cell proliferation proteins In preclinical studies z

  25. Slide 25: Preclinical Translation Regulation by Zotatifin Was Selective

    Preclinical regulation of translation by zotatifin was selective for proteins that drive tumor growth and resistance Zotatifin Target Sequence KRASmut protein all forms Cell proliferation/ cycle proteins RTK proteins Control protein unaffected Non-coding sequence coding sequence Experimental structu

  26. Slide 26: Activity Observed in ER+ and HER2+ Breast Cancer Models

    Activity observed as single agent and in combination in ER+ and HER2+ breast cancer models Zotatifin was observed to down-regulate multiple proteins that drive ER+, FGFR+ and HER2+ breast cancer, including: ER, FGFR, HER2, Cyclin D1, CDK4/6 In tumors driven by more than one of these factors, zotatif

  27. Slide 27: Single Agent and Combination Activity in KRAS NSCLC Model

    SINGLE AGENT AND COMBINATION ACTIVITY OBSERVED IN KRAS NSCLC MODEL NCI-H1792 NSCLC KRASG12C – Zotatifin mono showed similar activity as AMG510 in this model – Combination led to regressions in almost all animals Zotatifin (eFT226) showed strong synergy in cell proliferation and apoptosis assays in c

  28. Slide 28: Exposures in Dose Escalation Match Preclinical Activity

    Exposures achieved in dose escalation match exposures that showed activity in preclinical models P1 dose escalation ongoing, IV once weekly Long observed half-life of ~4 days has potential to maintain target suppression with intermittent dosing Zotatifin achieved target exposures in patients that sh

  29. Slide 29: Financial Overview

    financial OVERVIEW Top-tier Life Sciences Investors 2015 Series B 2013 Series A 2017 Series C Financial Highlights AbbVie Biotech Ventures $150M raised from top tier investors Up to $507M achievable under Pfizer agreement $42M received to date $465M potential additional development and sales milesto

  30. Slide 30: Multiple Upcoming Clinical Milestones

    Multiple upcoming clinical milestones 29

  31. Slide 31: Transaction Summary

    Transaction summary eF (OR

  32. Slide 32: Transaction Overview

    TRANSACTION OVERVIEW eFFECTOR has entered into a definitive agreement to merge with Locust Walk Acquisition Corp (“LWAC”) Implied post-money enterprise value of ~$420 million Transaction to be funded through a combination of $60 million committed PIPE financing plus up to $175 million from LWAC’s ca

  33. Slide 33: Transaction Overview: Valuation, Sources and Uses, Ownership

    TRANSACTION OVERVIEW Illustrative Post-Money Valuation at Close Illustrative Estimated Transaction Cash Sources and Uses Illustrative Post-Transaction Ownership Note: Assumes eFFECTOR cash balance of $17 million and debt balance of $20 million as of March 31, 2021, a $60 million PIPE issuance at $10

  34. Slide 34: Appendix

    Appendix Fi (OR

  35. Slide 35: Tomivosertib Is a Highly Selective MNK Inhibitor

    Tomivosertib is a highly selective mnk inhibitor Tomivosertib (eFT508) was tested against > 400 protein and lipid kinases at 1 mM concentration Reich et al. J. Med. Chem. 2018 61, 3516-3540. 34

  36. Slide 36: Tomivosertib Background – Preclinical Data Summary

    tomivosertib background - Preclinical data summary 35 Tomivosertib is an immunologically active agent Downregulated expression of checkpoint proteins, including PD-1,PD-L1, LAG-3 and TIM-3 Inhibited production of immunosuppressive cytokine IL-10 without interfering with interferon-g production Funct

  37. Slide 37: Tomivosertib Downregulates Key Immunosuppressive Factors in Activated T Cells

    Tomivosertib downregulates expression of key immunosuppressive factors in activated T cells Stimulated human primary T cells OT-I cells 36

  38. Slide 38: Tomivosertib Does Not Inhibit Interferon-g Expression

    Tomivosertib does not inhibit expression of immuno-stimulatory cytokine interferon-g IFN-g expressing T cells 37

  39. Slide 39: Tomivosertib Increased CD8+ T Cell/Treg Ratio

    Tomivosertib increased ratio of CD8+ T cells/Tregs and decreased M2 macrophage population In CT-26 syngeneic model (efficacy data on slide 11), treatment with tomivosertib increased ratio of CD8+/FOXP3+ cells and decreased M2 macrophages in tumor biopsies. Collaborators from McGill University indepe

  40. Slide 40: Tomivosertib Reprograms T Cells to Increase Central Memory Pool

    Target cell killing Tomivosertib Reprograms t cells from within to increase central memory pool and enhance cytotoxic function Central memory T cells mouse human 39

  41. Slide 41: Tomivosertib Increased T Cell Memory Pool

    Tomivosertib increased the T cell memory pool and increase was maintained beyond dosing period 40

  42. Slide 42: Zotatifin (eFT226) eIF4A Helicase Inhibitor – COVID-19

    Zotatifin (eFT226) eIF4A Helicase Inhibitor COVID-19: Designed to inhibit unwinding of complex RNA structures necessary to translate SARS-CoV-2 proteins

  43. Slide 43: Zotatifin Showed Potent In Vitro Activity Against Coronavirus Strains

    Zotatifin showed potent in vitro activity against multiple coronavirus strains eIF4A is required to unwind complex RNA secondary structures within the 5’ untranslated region (5’-UTR) of SARS-CoV-2 and other RNA viruses to translate polyprotein and replicate virus Drug screen published in Nature* rep

  44. Slide 44: Risk Factors

    RISK FACTORS Risks Related to Our Limited Operating History, Financial Position and Capital Requirements We have a limited operating history, have incurred significant operating losses since our inception and expect to incur significant losses for the foreseeable future. We may never generate any re

  45. Slide 45: Risk Factors (Cont'd)

    RISK FACTORS (Cont’d) Risks Related to Our Reliance on Third Parties We rely on third parties to conduct our clinical trials and preclinical studies. If these third parties do not successfully carry out their contractual duties, comply with applicable regulatory requirements or meet expected deadlin

  46. Slide 46: Risk Factors (Cont'd)

    RISK FACTORS (Cont’d) Risks Related to Our Business Operations and Industry Our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations or any guidance we may provide. We are depende

  47. Slide 47: Risk Factors (Cont'd)

    RISK FACTORS (Cont’d) Risks Related to Our Intellectual Property If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products similar or iden

  48. Slide 48: Risk Factors (Cont'd)

    RISK FACTORS (Cont’d) Risks Related to Becoming a Public Company We will incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives. We will be an emerging growth company and a smaller r

  49. Slide 49: Risk Factors (Cont'd)

    RISK FACTORS (Cont’d) There is no assurance that a stockholder’s decision whether to redeem its shares for a pro rata portion of LWAC’s trust account will put the stockholder in a better future economic position. If the Business Combination’s benefits do not meet the expectations of investors or sec

  50. Slide 50: Corporate Overview May 2021

    Corporate Overview May 2021 Next Generation Targeted Therapy for Cancer

eFFECTOR Therapeutics — SPAC Merger (May 2021) on 6ix